The effect of remifentanil on cardiac conduction system in pediatric patients undergoing radiofrequency catheter ablatio
Not Applicable
- Conditions
- Wolff-Parkinson-White syndrome
- Registration Number
- JPRN-UMIN000004150
- Lead Sponsor
- Department of Anesthesiology Japanese Red Cross Society Wakayama Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria 1) obesity 2) allergy to the trial or companion drugs 3) previous history of kidney, and/or liver disease. 4) patients with severe heart diseases including cardiomyopathy, valvulopathy, and congenital cardiac diseases 5) patients deemed unsuitable for the study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method After anesthetic induction and catheter insertion, CSACT (calculated sinoatrial conduction time) is measured during first EPS (electrophysiological study). And then, remifentanil is administered at a rate of 0.2 or 0.4 microg/kg/min. Almost 10 minutes after remifentanil administration, second EPS and CSACT measurement is performed.
- Secondary Outcome Measures
Name Time Method As with mentioned above, CSNRT (corrected sinus node recovery time), RR interval, and AH interval are measured before and during remifentanil administration.